ArticleCancer chemotherapy and pharmacology2018

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Jordi Rodon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.